MAM
EPZM

Meeder Asset Management’s Epizyme, Inc EPZM Stock Holding History

Meeder Asset Management’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-356
Closed -$6K – 2625
2020
Q1 		$6K Buy
356
+170
+91% +$3.65K ﹤0.01% 1747
2019
Q4 		$5K Buy
+186
New +$2.76K ﹤0.01% 1815
2019
Q3 		– Sell
-112
Closed -$1K – 2314
2019
Q2 		$1K Sell
112
-315
-74% -$4.05K ﹤0.01% 2001
2019
Q1 		$5K Buy
+427
New +$4.77K ﹤0.01% 1416
2018
Q2 		– Sell
-73
Closed -$1K – 1721
2018
Q1 		$1K Hold
73
– – ﹤0.01% 1505
2017
Q4 		$1K Buy
73
+31
+74% +$451 ﹤0.01% 1617
2017
Q3 		$1K Sell
42
-306
-88% -$4.67K ﹤0.01% 1587
2017
Q2 		$5K Buy
348
+183
+111% +$2.77K ﹤0.01% 1220
2017
Q1 		$3K Buy
165
+133
+416% +$1.77K ﹤0.01% 1296
2016
Q4 		$0 Buy
+32
New +$334 ﹤0.01% 1087

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Meeder Asset Management's EPZM Position: Q2 2020 in Review

Meeder Asset Management sold out of Epizyme, Inc (EPZM) in Q2 2020, closing a stake of 356 shares — an estimated $6K sold.

Meeder Asset Management first reported a position in EPZM in Q4 2016 and held it in 10 quarters. The position peaked at $6K in Q1 2020. 160 funds tracked by Wall St. Rank hold EPZM as of Q2 2020.

  • Meeder Asset Management reported no remaining Epizyme, Inc position as of Q2 2020 after selling out during the quarter.
  • Meeder Asset Management sold 356 Epizyme, Inc shares in Q2 2020, an estimated $6K.
  • Meeder Asset Management first reported a position in Epizyme, Inc in Q4 2016 and held it in 10 quarters.
  • Meeder Asset Management's Epizyme, Inc position peaked at $6K in Q1 2020.
  • 160 funds tracked by Wall St. Rank held Epizyme, Inc as of Q2 2020.

Based on Meeder Asset Management's 13F filing for Q2 2020, filed 11 Aug 2020.